New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

November 2016

Welcome to the November 2016 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the November issue!

The PharmSource Team

 

PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type October 2016 YTD 2016
Early Development 119 1186
Late Development 142 1187
Biologic 113 1036
Small Molecule 282 2569
Parenteral 104 1130
Oral 116 1003
New Financings 74 792
Total Drug Leads 382 3763
Total Device &
Diagnostic Leads
148 1412

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


 

Pipeline Tip

Biohaven Pharmaceutical plans to initiate a Phase II/III trial by Q1 of 2017 with BHV-4157 as a treatment for spinocerebellar ataxia:

  • Therapeutic Area: Neurology/CNS
  • Dosage Form: Oral
  • API: Chemical – Normal potency

Get deeper information about the likely upcoming needs of Biohaven, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.
 

Is R&D Productivity Improving?

by Saul Richmond, Director of Market Intelligence

In the past few years, approvals of new drugs have reached levels not seen for decades. The superficial reasons for this are clear: a combination of benign financial market conditions that have enabled companies to raise substantial amounts of cash, and regulatory authorities in Europe and the US that are committed to ensuring that novel therapies reach patients as quickly as possible.

However, funding tends to be cyclical in nature and 2016 looks like a year in which financial gravity has reasserted itself, with external markets resembling those encountered in the 2012-2013 period. In addition, drug approvals are likely to moderate. The more fundamental issue for the entire bio/pharma sector is… read on
 

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on Collegium Pharmaceutical, Inc.

Collegium is a U.S. public biopharmaceutical company that focuses on late-stage development and commercialization of pharmaceuticals for the treatment of CNS, respiratory and skin-related disorders. They plan to raise $80 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to commercialize Xtampza, a sustained-release oxycodone formulation developed using the DETERx oral delivery technology for the treatment of chronic pain, and… read on
 
 

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on Bigfoot Biomedical

Bigfoot Biomedical is a U.S. private company that develops a fully automated insulin delivery system for the management of type 1 diabetes. They raised $35.5 million in a completion of a Series A venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the development of its automated insulin delivery system… read on
 

New Business Opportunities in Medical Device & Diagnostic Companies

User Tip

If you’re looking to develop new business in medical device and diagnostic companies, or if you’d like to learn about this segment of the industry, you’ll be glad to hear we’ve expanded our coverage of this in the Devices & Diagnostics Edition of the PharmSource Lead Sheet.

Now, you can quickly know which companies in the medical device/diagnostic sector are expanding or contracting. In every issue, we tell you who’s restructuring, relocating or opening new facilities, downsizing or hiring,

You’ll find this information via the left navigation bar link for “Other Sponsor Events.” If you don’t currently subscribe to the Devices & Diagnostics Edition of the PharmSource Lead Sheet, please let us know if you’d like to learn more.

If you have any questions, please contact our Research Analyst, Scotty Chung-Siu at +1.703.383.4903 ext. 106 | scotty@pharmsource.com
 

Bio/Pharma Sponsor Spending on In-house Manufacturing Capacity Soars

This data-rich report, Bio/Pharma CapEx Trends 2016, identifies 3 indicators of what’s ahead for your business:

1. Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.

2. Bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years.

3. Based on recent capital expenditure trends, learn why bio/pharma companies would rather “make than buy.”


 

Celebrating 20 Years in Business!

Thank you to our clients, colleagues and friends. We look forward to many more years of successful business together.
 

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsouce.com / 1-703-383-4903, ext. 112 (ET USA).